| Field | Specification |
|---|---|
| Target | |
| Alternative names | Rab proteins geranylgeranyltransferase component A 1; Choroideremia protein; Rab escort protein 1; REP-1; TCD protein; CHM; REP1; TCD |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human CHM, which shares 88.9% amino acid (aa) sequence identity with both mouse and rat CHM. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes rab proteins geranylgeranyltransferase component A 1 (gene CHM) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 73.5 kDa, and the supplier reports an observed band at about 100 kDa.
Rab escort protein 1 (REP1, encoded by CHM) binds newly made Rab GTPases and presents them to Rab geranylgeranyltransferase for lipid modification. It then delivers the modified Rabs to membranes, and loss of REP1 causes choroideremia, an inherited degeneration of the retina and choroid.
| Target | Rab proteins geranylgeranyltransferase component A 1 (gene CHM; UniProt P24386, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 73.5 kDa |
| Observed MW | 100 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
Samples with a confirmed band (WB): human HeLa cells, human placenta tissue, human 293T cells, human A431 cells, human Caco-2 cells, human SiHa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human prostate cancer tissue, human thyroid cancer tissue, human tonsil tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): SiHa cells.
Samples with a confirmed signal (flow cytometry): U937 cells.
Immunogen
Synthetic peptide from the N-terminal region of human CHM. Sequence identity with the mouse and rat orthologs: 88.9%.
Reactivity Notes
The supplier lists reactivity with human. UniProt places rab proteins geranylgeranyltransferase component A 1 in the cytoplasm. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
